Delandistrogene moxeparvovec (SRP-9001) is an investigational rAAV vectorbased gene therapy, designed to compensate for missing functional dystrophin in Duchenne muscular dystrophy (DMD) by delivering a transgene encoding SRP-9001 dystrophin, an engineered dystrophin protein that retains key functional domains of the wild-type protein.Drawing on delandistrogene moxeparvovec clinical trial experience (Study 101 [SRP-9001-101; NCT03375164], Study 102 [SRP-9001-102; NCT03769116], and ENDEAVOR [Study 103; NCT04626674]), we outline several practical considerations for delandistrogene moxeparvovec administration in patients with DMD, including the observed time course of events, monitoring for and management of adverse events, and mitigation strategies.Considerations for initiating delandistrogene moxeparvovec treatment in patients with DMD include: (1) screening for elevated levels of anti-rAAVrh74 total binding antibodies before infusion; (2) assessing liver function, platelet count, and troponin I levels before administration; (3) monitoring liver function weekly (first 3 months post-infusion) and, if indicated, continuing monitoring until results are unremarkable; (4) postponing administration for patients with acute liver disease until disease control/resolution; (5) monitoring troponin I levels weekly (first month post-infusion), and continuing monitoring if indicated; and (6) administering corticosteroids starting 1 day prior to infusion (for patients already on corticosteroids), and maintaining the corticosteroid regimen for at least 60 days post-infusion, unless earlier tapering is indicated.Though the safety profile of delandistrogene moxeparvovec to date has been relatively consistent, monitorable, and manageable, clinical trial experience has led to important learnings and practical considerations that may mitigate the risk of adverse events following administration of delandistrogene moxeparvovec.